FLT3 and acute myeloid leukemia: The multiple class III RTK inhibitor midostaurin was approved by the FDA in 2017 for the treatment of FLT3-mutant AML, whereas the FDA rejected the selective FLT3 inhibitor quizartinib in 2019.